Geometric mean titres at various time points
| Participant group* | Indicator strain;† geometric mean titre (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|
| 44/76-SL | 5/99 | NZ98/254 | M10713 | UK P1.7–2,4 | GB101 | GB355 | GB364 | |
| 4CMenB 2,4,6,12,40 | ||||||||
| After 40-mo booster | 91 (55–151) n = 16 | 1786 (860–3708) n = 15 | 53 (26–106) n = 16 | 40 (24–67) n = 15 | 80 (36–181) n = 15 | 163 (78–338) n = 15 | 5.18 (2.98–9) n = 15 | 137 (51–371) n = 15 |
| At 60 mo | 4.68 (2.3–9.52) n = 16 | 136 (51–365) n = 16 | 4.95 (3.54–6.92) n = 16 | 10 (5.67–19) n = 16 | 8.91 (4.88–16) n = 16 | 3.43 (2.04–5.76) n = 16 | 1.66 (1.13–2.44) n = 16 | 39 (15–99) n = 16 |
| rMenB 2,4,6,12,40 | ||||||||
| After 40-mo booster | 107 (70–163) n = 23 | 819 (454–1477) n = 23 | 1.74 (0.97–3.13) n = 23 | 46 (30–69) n = 23 | 6.86 (3.56–13) n = 23 | 64 (36–116) n = 23 | 1.88 (1.2–2.93) n = 23 | 41 (18–91) n = 23 |
| At 60 mo | 3.13 (1.75–5.59) n = 24 | 43 (19–99) n = 23 | 1.05 (0.8–1.38) n = 24 | 12 (7.22–20) n = 22 | 1.76 (1.08–2.87) n = 24 | 2.16 (1.4–3.33) n = 23 | 1 (0.73–1.38) n = 23 | 8.74 (3.94–19) n = 22 |
| 4CMenB 12,40,42 | ||||||||
| After immunization at 42 mo | 136 (62–299) n = 5 | 3351 (1537–7305) n = 5 | 79 (23–274) n = 5 | 28 (6.99–112) n = 5 | 69 (21–228) n = 5 | 113 (40–320) n = 5 | 12 (6.02–25) n = 5 | 227 (45–1146) n = 5 |
| At 60 mo | 13 (3.52–45) n = 5 | 210 (36–1227) n = 5 | 11 (5.93–20) n = 5 | 25 (8.47–74) n = 5 | 34 (11–98) n = 5 | 11 (4.53–29) n = 5 | 4.68 (2.36–9.28) n = 5 | 20 (3.78–107) n = 5 |
| rMenB 12,40,42 | ||||||||
| After immunization at 42 mo | 127 (78–207) n = 13 | 5240 (3232–8497) n = 13 | 1.86 (0.86–4.03) n = 13 | 21 (8.56–51) n = 12 | 3.03 (1.4–6.55) n = 12 | 43 (22–85) n = 12 | 1.29 (0.81–2.05) n = 12 | 616 (217–1750) n = 12 |
| At 60 mo | 18 (8.08–39) n = 13 | 369 (123–1103) n = 13 | 1 (0.69–1.45) n = 13 | 12 (5.85–24) n = 12 | 1.39 (0.67–2.88) n = 11 | 3.01 (1.65–5.47) n = 12 | 1.35 (0.85–2.14) n = 11 | 39 (13–114) n = 12 |
| 4CMenB 40,42 | ||||||||
| After immunization at 40 and 42 mo | 82 (57–117) n = 27 | 888 (645–1222) n = 27 | 42 (24–72) n = 27 | 38 (23–62) n = 27 | 29 (19–44) n = 26 | 192 (98–376) n = 26 | 7.39 (3.76–14) n = 26 | 103 (68–157) n = 26 |
| At 60 mo | 12 (6.27–23) n = 28 | 44 (29–67) n = 28 | 2.42 (1.59–3.66) n = 29 | 8.52 (5.09–14) n = 27 | 2.87 (1.96–4.18) n = 27 | 11 (5.4–22) n = 27 | 2.93 (1.74–4.93) n = 27 | 15 (9.06–25) n = 27 |
| 4CMenB 60,62 | ||||||||
| At 60 mo, before immunization | 2.98 (1.86–4.78) n = 46 | 1.14 (0.88–1.47) n = 46 | 1.04 (0.96–1.14) n = 46 | 18 12–28) n = 46 | 1.34 (1.07–1.68) n = 46 | 2.27 (1.62–3.18) n = 46 | 1.15 (0.96–1.37) n = 46 | 2.24 (1.54–3.26) n = 46 |
| After immunization at 60 and 62 mo | 34 (23–50) n = 39 | 875 (546–1404) n = 39 | 29 (21–41) n = 39 | 42 (32–54) n = 39 | 37 (26–51) n = 39 | 14 (9.92–21) n = 39 | 3.99 (2.71–5.87) n = 39 | 97 (63–151) n = 39 |
Note: 4CMenB = multicomponent serogroup B meningococcal vaccine, rMenB = recombinant protein serogroup B meningococcal vaccine, CI = confidence interval.
↵* 4CMenB 2,4,6,12,40 = 4CMenB vaccine administered at 2, 4, 6, 12 and 40 months; rMenB 2,4,6,12,40 = rMenB vaccine administered at 2, 4, 6, 12 and 40 months; 4CMenB 12,40,42 = 4CMenB vaccine administered at 12, 40 and 42 months; rMenB 12,40,42 = rMenB vaccine administered at 12, 40 and 42 months; 4CMenB 40,42 = 4CMenB vaccine administered at 40 and 42 months; 4CMenB 60,62 = 4CMenB vaccine administered to newly recruited vaccine-naive children at 60 and 62 months.
↵† Indicator strains were selected to assess specific antigens, as follows: strain 44/76–SL for factor H binding protein, strain 5/99 for Neiserria adhesin A, NZ98/254 strain for outer membrane vesicle and M10712 strain for Neiserria heparin-binding antigen. The other indicator strains were not matched to vaccine components.